Lu Ping, Wang Ya-Jie, Zheng Ya-Wei, Dong Fang, Pang Ya-Kun, Cheng Hui, Yuan Wei-Ping, Cheng Tao, Hao Sha
State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Apr;23(2):306-11. doi: 10.7534/j.issn.1009-2137.2015.02.003.
BACKGROWND: Macrophage inflammatory protein-1α (MIP-l α/CCL3) belongs to the C-C chemokine family (CCL3), which can be secreted by macrophages, other types of hematopoietic cells and bone marrow stromal cells. Higher levels of MIP-1α were found to be associated with several kinds of hematologic malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). Moreover, MIP-1α has been reported to be an adverse prognostic factor for CLL. However, the impact of MIP-1α on acute myeloid leukemia (AML) has been poorly investigated.
To investigate the influence of MIP-1α on proliferction of AML cells.
Using MLL-AF9 induced AML mouse model, the expression of MIP-1α was measured by real time quantitative RT-PCR. AML cell proliferation was examined by cell counting and colony forming assay (CFC). The influence of blocking the MIP-1α action on the growth and pathogenic ability of AML cells was explored by using the small molecule antagonist for interfering interaction of MIP-1α with its receptor CCR1.
The MIP-1α could promote the proliferation and colony formation of AML cells, the blocking MIP-1a could inhibit the growth of AML cells and delay onset of AML.
The MIP-1a promotes the occurence and progression of AML, therefore blocking the MIP-1α signal pathway may be served as a strategy to inhibit the growth of AML cells, and MIP-1α can be a potential target for treatment of AML.
背景:巨噬细胞炎性蛋白-1α(MIP-1α/CCL3)属于C-C趋化因子家族(CCL3),可由巨噬细胞、其他类型造血细胞及骨髓基质细胞分泌。研究发现,MIP-1α水平升高与多种血液系统恶性肿瘤相关,包括多发性骨髓瘤(MM)、慢性淋巴细胞白血病(CLL)和慢性髓性白血病(CML)。此外,据报道MIP-1α是CLL的不良预后因素。然而,MIP-1α对急性髓性白血病(AML)的影响尚未得到充分研究。
探讨MIP-1α对AML细胞增殖的影响。
利用MLL-AF9诱导的AML小鼠模型,通过实时定量RT-PCR检测MIP-1α的表达。采用细胞计数和集落形成试验(CFC)检测AML细胞增殖情况。使用小分子拮抗剂干扰MIP-1α与其受体CCR1的相互作用,探讨阻断MIP-1α作用对AML细胞生长和致病能力的影响。
MIP-1α可促进AML细胞的增殖和集落形成,阻断MIP-1α可抑制AML细胞生长并延缓AML发病。
MIP-1α促进AML的发生和发展,因此阻断MIP-1α信号通路可能是抑制AML细胞生长的一种策略,MIP-1α可成为治疗AML的潜在靶点。